Scholarlink

<p>This article reports two cases of stage IIIB small cell lung cancer (SCLC) patients who underwent neoadjuvant immunotherapy combined with chemotherapy, resulting in markedly different clinical outcomes, and explores the potential molecular mechanisms behind these differences. Both patients were diagnosed with stage IIIB small cell lung cancer through imageological examination and CT-guided percutaneous lung biopsy. They received three cycles of neoadjuvant treatment with “etoposide + carboplatin + serplulimab” followed by surgical resection of the lesions. Genetic testing for solid tumors was conducted before and after treatment. The results showed that Case 1 exhibited multiple gene mutations, including <i>FBXW7</i> and <i>KRAS</i>, with a tumor mutational burden (TMB) of 17.65 muts/Mb before treatment. After neoadjuvant therapy, only the <i>PTEN</i> mutation remained, and TMB decreased to 0.00 muts/Mb, with no cancer cells observed in the postoperative pathology, leading to an assessment of pathological complete response (pCR). In contrast, Case 2 showed <i>MET</i> and <i>PTEN</i> mutations and <i>MYC</i> gene amplification both before and after treatment, with TMB increasing from 23.72 muts/Mb to 28.13 muts/Mb, resulting in an assessment of disease progression (PD) post-surgery. This study emphasizes the potential value of neoadjuvant therapy in locally advanced SCLC patients and highlights the importance of genetic testing in predicting treatment responses and guiding personalized treatment strategies. Further research is needed to explore more effective therapeutic strategies to improve the prognosis of SCLC patients. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Divergent outcomes of neoadjuvant therapy for locally advanced small-cell lung cancer: two cases report and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月7日

查看全文
  • Dongfang Qiao,
  • Ziqing Xu,
  • Yizhuo Chen,
  • Zhouqi Zhang,
  • Dongrui Feng,
  • Xin Wang,
  • Ming Dong

摘要

This article reports two cases of stage IIIB small cell lung cancer (SCLC) patients who underwent neoadjuvant immunotherapy combined with chemotherapy, resulting in markedly different clinical outcomes, and explores the potential molecular mechanisms behind these differences. Both patients were diagnosed with stage IIIB small cell lung cancer through imageological examination and CT-guided percutaneous lung biopsy. They received three cycles of neoadjuvant treatment with “etoposide + carboplatin + serplulimab” followed by surgical resection of the lesions. Genetic testing for solid tumors was conducted before and after treatment. The results showed that Case 1 exhibited multiple gene mutations, including FBXW7 and KRAS, with a tumor mutational burden (TMB) of 17.65 muts/Mb before treatment. After neoadjuvant therapy, only the PTEN mutation remained, and TMB decreased to 0.00 muts/Mb, with no cancer cells observed in the postoperative pathology, leading to an assessment of pathological complete response (pCR). In contrast, Case 2 showed MET and PTEN mutations and MYC gene amplification both before and after treatment, with TMB increasing from 23.72 muts/Mb to 28.13 muts/Mb, resulting in an assessment of disease progression (PD) post-surgery. This study emphasizes the potential value of neoadjuvant therapy in locally advanced SCLC patients and highlights the importance of genetic testing in predicting treatment responses and guiding personalized treatment strategies. Further research is needed to explore more effective therapeutic strategies to improve the prognosis of SCLC patients.